# NewBridge Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/newbridge-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Dubai, United Arab Emirates
- Website: www.nbpharma.com
- Total disclosed funding: $12M
- Latest round: Series B (Sep 20, 2010)
- Investors on record: 2

## About

NewBridge Pharmaceuticals is a pharmaceutical company specializing in the commercialization of innovative therapies through in-licensing agreements. It focuses primarily on improving patient access to advanced healthcare solutions in the MENA region.NewBridge Pharmaceuticals operates as a specialized commercialization platform, actively engaging in the in-licensing of innovative healthcare solutions from global pharmaceutical firms. The company is headquartered in Dubai, United Arab Emirates. Founded by a team with extensive experience in the pharmaceutical industry, NewBridge has raised a total of USD 12.00 mn through a Series B financing round on September 20, 2010, led by Burrill & Company and National Technology Enterprises Company. It has completed one major deal to date.NewBridge Pharmaceuticals operates as a First-in-Class commercialization platform, focusing on the in-licensing of innovative therapies from global pharmaceutical firms. The company primarily serves the MENA region, striving to bridge the access gap for patients in these countries. Their core product offerings are centered around advanced therapeutic solutions designed to address critical healthcare needs across various therapy areas. NewBridge Pharmaceuticals is dedicated to ensuring that life-saving therapies reach markets including but not limited to Saudi Arabia, Egypt, Lebanon, and Morocco.NewBridge Pharmaceuticals generates revenue through partnerships and collaborations with global pharmaceutical companies, focusing on the commercialization and distribution of licensed products in the MENA region. Their revenue model is structured around agreements that enable the company to bring innovative therapies to market, creating pathways for B2B partnerships with healthcare providers and potential direct interactions with consumers via healthcare channels. The company’s strategic emphasis on early access programs further suggests a revenue stream based on enabling patient access to essential medications alongside healthcare providers.NewBridge Pharmaceuticals intends to leverage its recent funding of USD 12.00 mn from the Series B round to enhance its product portfolio and expand into new markets within the MENA region. The company is currently developing additional therapeutic solutions, with plans to launch new products aimed at addressing unmet medical needs. The funding will also facilitate market entry into regions like Morocco and Egypt by 2023, aligning with the company's strategy to widen access to its innovative therapies in underserved markets.

## Funding rounds

- Series B, Sep 20, 2010, $12M — Burrill & Company, National Technology Enterprises Company

## Investors

- Burrill & Company (https://capitalatlas.ai/funds/burrill-company) — Series B
- National Technology Enterprises Company — Series B